The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of Recchia's immunomodulatory schedule (RIS) as a maintenance therapy in high-risk tumors after a response.
Manuel Sureda
No relevant relationships to disclose
Joseba Rebollo
No relevant relationships to disclose
Begona Vazquez
No relevant relationships to disclose
Pere Bretcha
No relevant relationships to disclose
Rosa CaƱon
No relevant relationships to disclose
Maritza Duarte
No relevant relationships to disclose
Vicente Munoz
No relevant relationships to disclose
Antonio Brugarolas
No relevant relationships to disclose